Researchers at Great Ormond Street Hospital for Children (GOSH) and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH) have used CRISPR/Cas9 technology to engineer donor T cells to try to treat seriously ill children with resistant leukemia, who had otherwise exhausted all available therapies.
This Phase I trial, published in Science Translational Medicine, uses ‘universal’ CRISPR-edited cells in humans and represents a step forward in the use of gene-edited cells for cancer treatment. As part of the trial the research team, built and applied a new generation of ‘universal’ genome-edited T cells, which builds on previous work1 that had used older, less accurate technology.
T cells were modified using CRISPR which makes a cut in the cells’ DNA and insert a genetic code. In this case this piece of genetic code allows the T cells to express a receptor - called a chimeric antigen reception (CAR) - that can recognize a marker on the surface of cancerous B cells and then destroy them. The T cells were then gene edited using CRISPR so that they could be used ‘off the shelf’ without any donor matching needed.
While a number of CAR T-cell therapies are now being provided by the National Health Service, they rely on collecting and engineering a patient’s own cells. This is expensive and is not always feasible or possible in a short period of time. Genome editing is being investigated to allow donated cells to be pre-manufactured and used in multiple patients, aiming to reduce costs and make the treatments more accessible.
In specialist clean rooms at GOSH, researchers manufactured their banks of donor CAR T-cells using a single disabled virus to transfer both the CAR and a CRISPR guidance system, and then applied cutting-edge mRNA technology to activate the gene editing steps. Donors were all healthy volunteers from the UK and provided by the Anthony Nolan Registry.
Six children aged 14 months to 11 years with relapsed and treatment-resistant B-ALL have been treated up to February 2022. All of the children had previously been through standard UK treatments for B-ALL but had sadly seen their disease return multiple times.
Patients were infused with the edited cells that were expected to be active for around four weeks. This is long enough to hopefully achieve deep remission, a state where their cancer is dramatically reduced or undetectable. When successful, patients were then eligible to follow through with a bone marrow stem cell transplant to help re-establish a healthy immune system.
Four of the first six children treated entered remission within 28 days, which allowed them to receive a stem cell transplant. Of those four children, two children remain in ongoing remission 9 months and 18 months after treatment respectively, while sadly two relapsed following their stem cell transplant.
In this study overall side effects were within expectations and were managed in hospital, with one patient requiring a short period of intensive care.
